Anderson David W 4

4 · ALPHA HEALTHCARE ACQUISITION CORP III · Filed Jul 18, 2023

Form 4

Period: 2023-07-14

Director

Transactions

Award
Stock Option (right to buy)
2023-07-14+16,285→ 16,285 total
Exercise: $1.79Exp: 2026-07-16→ Common Stock (16,285 underlying)
Award
Stock Option (right to buy)
2023-07-14+19,910→ 19,910 total
Exercise: $1.79Exp: 2027-06-20→ Common Stock (19,910 underlying)
Award
Stock Option (right to buy)
2023-07-14+8,509→ 8,509 total
Exercise: $2.27Exp: 2029-07-19→ Common Stock (8,509 underlying)
Award
Stock Option (right to buy)
2023-07-14+32,173→ 32,173 total
Exercise: $2.11Exp: 2031-09-23→ Common Stock (32,173 underlying)

Footnotes (4)

[F1]Options are fully vested and exercisable.
[F2]Options to purchase 8,509 shares of common stock of Legacy Carmell (as defined below) granted on July 19, 2019, which vest as follows: (i) 25% vested on July 19, 2020, July 19, 2021 and July 19, 2022 and the remaining 25% will vest on July 19, 2023.
[F3]Options to purchase 32,173 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
[F4]On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.

Documents

1 file